CSPC Innovation Pharmaceutical (SHE:300765) subsidiary CSPC Jushi Biopharmaceutical presented clinical results of its two self-developed drugs at the 2026 European Society for Medical Oncology Congress, according to a Wednesday filing with the Shenzhen bourse.
Its SYS6043 showed strong anti-tumor activity and manageable safety across various advanced breast cancer subtypes, while the SYS6090 showed preliminary efficacy against advanced solid tumors, including liver and colorectal cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments